Amryt Pharma Share Discussion Threads

[papillon] 07/2/2017 20:32

Being able to buy below the notional mid price is often a sign that the share price has further to fall, speecy.

Yes, Buffy, what you say is true. Unfortunately the news that AMYT is currently issuing (RNS's yesterday and today) is not ground breaking enough to propel the share price upwards unlike the two RNS's issued in December.

[speccy1] 07/2/2017 19:13

Interesting that all the transactions are showing as sells today. My 5,734 at 17.27p was a buy, so I suspect most of the trades 7.2p-7.3p could be buys and the spread could be much narrower than it looks.

[buffythebuffoon] 07/2/2017 15:04

No, there isn't currently. That's often how it is with biopharmas; but it can change dramatically. Hence the attraction.

Buffy

[papillon] 07/2/2017 11:31

Jacksonpollack7 Feb '17 - 08:10 - 813 of 816 0 0
SP rise Would be nice but not going to happen. No interest here

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Unfortunately I have to agree with JP. There is currently very little investor interest in AMYT.

[pottermagic2310] 07/2/2017 09:17

I firmly believe this Business is demonstrating some nouse in this Sector and is actually delivering against the Business Plan.
I'm not convinced our Product is a massive 'earner' anytime soon but am pleased positive, constructive steps forward are being achieved and viable Product(s) may hit their target Market(s) eventually and to everybody's benefit.
It's a HOLD for me 'til this time next year... assuming there is no very bad News out of the blue in the meantime

[icebreaker] 07/2/2017 08:52

For me the only real interest in this RNS is the fact that P3 is still going ahead in this quarter (late Q1); this being the only short term share price driver that I am aware of.

I think they will deliver a further RNS on this now that they have confirmed it. Hopefully this week.

[gnnmartin] 07/2/2017 08:26

Surprising lack of interest.

[jacksonpollack] 07/2/2017 08:10

SP rise Would be nice but not going to happen. No interest here

[888icb] 07/2/2017 07:23

Good news two days running so it would be nice to see the share price rise.

[icebreaker] 07/2/2017 07:11

Still on track for P3 'late' Q1

[papillon] 06/2/2017 23:54

sp up today on low volume. Not bullish IMO

[punter6] 06/2/2017 09:33

Well it ain't bad news anyway.

[icebreaker] 06/2/2017 09:06

Novartis will be watching this...

AP102 could replace Sandostatin and Amyt look cheap at £37M MC.

[jacksonpollack] 06/2/2017 07:44

Progress, lol. So the rats diabetes didn't get any worse. Not exactly earth shattering news. Probably be radio silence here for the next 6mths as the bod will think they have done enough for now throwing a few crumbs to long suffering shareholders.

[bigwavedave] 06/2/2017 07:40

Excellent progress.

[papillon] 03/2/2017 12:22

Looks likely that the AMYT share price has further to fall in the short term in the continuing absence of news.

[papillon] 01/2/2017 14:02

2 big sells this morning before 9am. Reporting of both delayed by 1 hour.

92,500 @ 7.10p and then 5 mins later 90,744 at just 16.1375p, well below the then quoted 17p bid price. They must have been very keen to sell! Could both trades be by the same seller? Possible as 90,744 seems an odd amount. Could have been the seller finally offloading his remaining shares?

Perhaps it as JP? LOL.

[papillon] 31/1/2017 23:15

I think you need to wait and see what happens here in the next few years before making such a rash judgement on the AMYT BoD, JP.

You might turn out to be correct, JP, but at the moment it's too early to make a judgement IMO. FAST turned out to be a disaster for shareholders, but AMYT is still less than 9 months old. I'm going to give it a chance even if you're not. Personally if I thought as you do I would sell my shares, because you obviously have no confidence in the BoD. You seem to believe they are a bunch of money grabbing time wasters. You could turn out to be correct, but give them a chance to prove you wrong; I am.

[jacksonpollack] 31/1/2017 19:30

The bod here are living the aim dream, lol. Money for nothing.

[icebreaker] 31/1/2017 09:06

I agree with your last sentence Papillon.

The concern is not necessarily that there is not a stream of RNS's, more that there is very little other information out there on which to base an informed investment decision. I know about the company simply because my shares in Fastnet were converted to those of Amryt. I am not sure I would have heard of Amryt otherwise.

As an example, we (apparently) gave a presentation in San Francisco a week or so ago and yet there is no evidence that I can see that it took place. It would have been helpful to put the presentation out there, or at least on the company's web-site.

The key is progress. If the private investor is not getting to see our board taking the business forward such that they can form an opinion, then I suspect its the same with the larger investors/institutions.

We all think the story that is unfolding (from what we can see) is a good one, but the volumes would indicate to me that the wider community do not share this view (yet) or are simply not aware. Personally, I think the company needs to look at its PR. The 2 news items prior to Xmas gave me the confidence to continue holding, however the markets response was subdued!

[papillon] 26/1/2017 10:32

Interesting post on the lse bb.

equitrder
Posts: 582
Off Topic
Opinion: No Opinion
Price: 18.50
If we get it right? Today 09:44 J&J Seals $30 Billion Actelion Deal to Enter Rare Disease Arena

Actelion shareholders to get $280/share in cash in deal
Drugmakers expect deal to be completed in second quarter
Johnson & Johnson agreed to buy Actelion Ltd. for $30 billion and spin off the Swiss drugmaker’s research and development operations, clinching its largest deal ever to become a leader in medicines treating a rare type of high blood pressure.

J&J, already the world’s biggest maker of health-care products, is fulfilling its goal of adding a new drug category with the transaction and dealing a blow to France’s Sanofi, which had also sought to acquire Actelion. The deal is expensive compared to recent industry takeovers such as Pfizer Inc.’s acquisition of Medivation Inc. and AbbVie Inc.’s purchase of Pharmacyclics Inc., according to an analysis from Bloomberg Intelligence.

J&J will begin a tender offer to buy shares of Allschwil, Switzerland-based Actelion for $280 each in cash, the companies said in a statement. The price, which equals 280.08 Swiss francs, is 23 percent above Wednesday’s closing level. The R&D operations will be spun off to Actelion shareholders as a new publicly traded company, with J&J keeping a 16 percent stake

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

AMYT shareholders can dream!! I am!!

[gnnmartin] 26/1/2017 00:30

I agree, icebreaker. We may be reading more than intended, but if they were confident of the 1Q, they could still say 'this quarter'.